Xact Kapitalforvaltning AB boosted its holdings in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 21.1% during the second quarter, Holdings Channel.com reports. The fund owned 8,623 shares of the biopharmaceutical company’s stock after acquiring an additional 1,500 shares during the period. Xact Kapitalforvaltning AB’s holdings in Ultragenyx Pharmaceutical were worth $548,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of RARE. Bank of New York Mellon Corp boosted its holdings in Ultragenyx Pharmaceutical by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 207,926 shares of the biopharmaceutical company’s stock worth $9,040,000 after buying an additional 661 shares during the period. Northern Trust Corp raised its position in shares of Ultragenyx Pharmaceutical by 2.0% during the 4th quarter. Northern Trust Corp now owns 580,580 shares of the biopharmaceutical company’s stock valued at $25,243,000 after buying an additional 11,258 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Ultragenyx Pharmaceutical by 120.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 136,555 shares of the biopharmaceutical company’s stock valued at $5,936,000 after buying an additional 74,608 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Ultragenyx Pharmaceutical by 4.0% during the 4th quarter. California State Teachers Retirement System now owns 74,783 shares of the biopharmaceutical company’s stock valued at $3,252,000 after buying an additional 2,851 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 12.5% during the 4th quarter. Geode Capital Management LLC now owns 568,230 shares of the biopharmaceutical company’s stock valued at $24,706,000 after buying an additional 63,118 shares in the last quarter.

RARE stock traded down $1.72 during mid-day trading on Monday, reaching $60.53. The company had a trading volume of 6,207 shares, compared to its average volume of 389,520. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.77 and a quick ratio of 11.60. The stock has a market cap of $3.58 billion, a P/E ratio of -8.17 and a beta of 2.17. The business has a 50 day moving average of $60.49. Ultragenyx Pharmaceutical Inc has a 12 month low of $37.44 and a 12 month high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.09). The company had revenue of $18.17 million during the quarter, compared to the consensus estimate of $18.75 million. Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. Ultragenyx Pharmaceutical’s revenue was up 70.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc will post -6.96 EPS for the current fiscal year.

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 1,226 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $61.50, for a total value of $75,399.00. The sale was disclosed in a filing with the SEC, which is available through this link. 7.80% of the stock is owned by corporate insiders.

A number of analysts recently weighed in on the stock. ValuEngine lowered shares of United Rentals from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 18th. BidaskClub lowered shares of YY from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 23rd. Zacks Investment Research lowered shares of Guaranty Federal Bancshares from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Barclays reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, May 9th. Finally, Wedbush reissued a “hold” rating and issued a $9.00 price objective on shares of Glu Mobile in a research report on Tuesday, May 7th. Three research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $77.47.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Further Reading: How Do Mutual Funds Work?

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.